ABSTRACT
INTRODUCTION Amantadine and anticholinergics have been used for several decades as therapy for Parkinson’s disease (PD). In spite of reduced interest in these compounds with the advent of more specifi c dopaminergic therapies, there remain clinical situations where amantadine and anticholinergics retain clinical usefulness and a role in the contemporary treatment of PD. In fact, in the last few years, amantadine is being prescribed more frequently to treat patients experiencing dyskinesia.
